Segment Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($) segment	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)
Segment Reporting Information [Line Items]
Number of reportable segments | segment	2
Total revenue	$ 6,761	$ 6,482	$ 4,227
Cost of revenue	4,713	5,133	4,055
Research and development	43,813	29,338	64,165
General and administrative	23,619	20,530	27,827
Revaluation of contingent consideration	24,339	2,393	734
Goodwill impairment			18,504
Amortization expense	75	75	75
Loss from operations	(89,723)	(50,912)	(111,058)
Loss from discontinued operations		139	(49,234)
Income (loss) from discontinued operations		139	(47,812)
Dermatology Therapeutics Segment
Segment Reporting Information [Line Items]
Total revenue	932	696
Research and development	44,259	29,777	64,564
General and administrative			620
Revaluation of contingent consideration	24,339	2,393	734
Goodwill impairment			18,504
Loss from operations	(67,666)	(31,474)	(84,422)
Income (loss) from discontinued operations		140	(46,305)
Contract Research Segment
Segment Reporting Information [Line Items]
Total revenue	13,447	13,319	16,824
Cost of revenue	11,885	12,228	16,253
General and administrative	3,047	2,794	2,738
Loss from operations	(1,485)	(1,703)	(2,167)
Corporate and Other
Segment Reporting Information [Line Items]
Total revenue	(7,618)	(7,533)	(12,597)
Cost of revenue	(7,172)	(7,095)	(12,198)
Research and development	(446)	(439)	(399)
General and administrative	20,572	17,736	24,469
Loss from operations	(20,572)	(17,735)	(24,469)
Income (loss) from discontinued operations		(1)	(1,507)
Intersegment Eliminations | Contract Research Segment
Segment Reporting Information [Line Items]
Total revenue	$ 7,600	$ 7,500	$ 12,600